Most U.S. adults with type 2 diabetes (T2D) meet recommended criteria for use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is), but fewer than 10 percent use either of them, according to a research letter published online Feb. 28 in the Annals of Internal Medicine.
Source: Medical Xpress